Hansa Biopharma: Interview with CEO Søren Tulstrup (video)

Research Interview



Hansa Biopharma's CEO Søren Tulstrup provides an update and an interesting insight into Hansa's European launch of Imlifidase. The product was recently approved, giving hope and future life for these highly sensitized patients stuck in a queue waiting for a new kidney. This journey towards a future life includes gradual progress, extending the number of reference specialist centers using Imlifidase, expanding the number of countries reimbursing Imlifidase and eventually a much-improved standard of care for these patients in Europe and beyond.


Johan Unnerus

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.